Latest News About - Roseolo virus

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Thursday, April 22, 2021

3:43:00 PM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ab
ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
gl
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
my
ne
nl
no
os
pap
pl
ps
pt
ro
ru
se
si
sk
sl
so
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Most reported countries (24h)

Theme countries

AlertLevel (24h)

Alert level graph

 Previous 14 days average

Alert level:
 high   medium   low

Quotes... Extracted quotes

Liana Moussatos noted: “In 2021, we look forward to 1) TC-hGH/pediatric growth hormone deficiency (GHD; lonapegsomatropin) June 25, 2021, PDUFA date; 2) potential TC-hGH/GHD MAA approval in Q4:21; and 3) topline results from the pivotal Phase 3 PaTHway for TCPTH in adult hypoparathyroidism (HP) in Q4:21. We see these events as potential inflection points for the stock. We expect 2021 to be a transformative year for Ascendis in front of several potential value creation events,” External link

news-yahoo Friday, April 9, 2021 12:44:00 PM CEST

Frank Neumann said: “Tecartus has already begun to transform the outlook for many patients with relapsed or refractory mantle cell lymphoma, and we’re encouraged by the data we’ve seen in adult patients with relapsed or refractory ALL, as survival rates among these patients remain poor with the most commonly used therapeutic agents,” External link

4-traders Thursday, April 1, 2021 10:20:00 PM CEST

Bhupesh Prusty sagt: „Auf diese Weise werden wir in der Lage sein besser zu verstehen, wie Krankheitserreger, insbesondere Herpesviren wie HHV-6, spezifische menschliche Zellen einschließlich der Immunzellen verändern, um diese Krankheiten zu verursachen“ External link

idw-online Wednesday, March 17, 2021 8:32:00 AM CET

Frank Neumann said: “As we work to bring the benefits of Yescarta to more patients, these results provide important insights into the use of Yescarta in LBCL, and for safety management protocols for trials with our CAR T-cell therapies,” External link

4-traders Wednesday, February 10, 2021 11:21:00 PM CET

Daily number of articles in this category

Trend data not available for this selection.